 |
 |

Low-Dose Proton Beam Therapy for Circumscribed Choroidal Hemangiomas
Eric Frau, MD;
Frank Rumen, MD;
George Noel, MD;
Sabine Delacroix, PhD;
Jean-Louis Habrand, MD;
Hervé Offret, MD
Arch Ophthalmol. 2004;122:1471-1475.
Objective To evaluate the efficacy and safety of proton beam therapy for complicated circumscribed choroidal hemangiomas.
Methods The study was a retrospective nonrandomized investigation. Seventeen consecutive patients, referred to the Institut Gustave-Roussy, Villejuif, France, for circumscribed choroidal hemangioma associated with serous retinal detachment were studied. Each eye received a total dose of 20 cobalt gray equivalents (CGEs) delivered in 15-second fractions of 5 CGEs over 4 days. Functional tests included the initial and final best-corrected visual acuity, slitlamp examination, intraocular pressure, fundus examination, fluorescein angiography, and indocyanine green angiography. Tumor thickness was determined on B-scan ultrasonography.
Results The macula was involved in 7 eyes and the lesion was juxtapapillary in 2 eyes. The mean (SD) tumor thickness was 3.06 (9.0) mm. The mean initial tumor diameter was 6.82 mm (range, 3.2-12.1 mm). The right eye was involved in 7 cases and the left eye in 10 cases. The mean (SD) follow-up period was 52 (58) months (range, 36-90 months). Retinal reattachment was obtained in all cases after a mean period of 2 months (range, 1-12 months; median, 1 month). Tumor regression was obtained in all cases. One recurrence occurred 1 year after the initial treatment in an undertreated area. After re-treatment, however, resolution of the retinal detachment occurred, and flattening of the choroidal lesion was obtained. Final visual acuity improved to 2 Snellen lines or more in 16 eyes (94%), was stable in 1 eye, and attained 20/40 or more in 12 eyes (70.6%). No radiation therapy complications occurred during follow-up.
Conclusions Proton beam therapy for choroidal hemangiomas seems to be an effective and safe alternative option. A total dose of 20 CGEs delivered in 4 daily 15-second fractions of 5 CGEs seems adequate for local control of both the tumor and serous retinal detachment.
From the Institut Gustave-Roussy, Villejuif, France (Drs Frau and Habrand); Service d'Ophtalmology, Centre Hospitalier et Universitaire de Bicêtre, Paris, France (Drs Frau, Rumen, and Offret); and the Centre de Protonthérapie d'Orsay, Campus Universitaire, Orsay, France (Drs Noel and Delacroix). The authors have no relevant financial interest in this article.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|